



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/00	A2	(11) International Publication Number: WO 99/08668 (43) International Publication Date: 25 February 1999 (25.02.99)
(21) International Application Number: PCT/US98/16849 (22) International Filing Date: 13 August 1998 (13.08.98) (30) Priority Data: 60/055,891 15 August 1997 (15.08.97) US (71) Applicant (for all designated States except US): CEPHALON, INC. [US/US]; 145 Brandywine Parkway, West Chester, PA 19380 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DIONNE, Craig, A. [US/US]; 106 Victoris Court, Downingtown, PA 19335 (US). ISAACS, John [US/US]; 13638 Poplar Hill Road, Phoenix, MD 21131 (US). VAUGHT, Jeffry, L. [US/US]; 206 Kathleen Way, Glenmoore, PA 19343 (US). (74) Agent: CREASON, Gary, L.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: COMBINATION OF TYROSINE KINASE INHIBITOR AND CHEMICAL CASTRATION TO TREAT PROSTATE CANCER (57) Abstract A method of treating prostate cancer by coadministering a tyrosine kinase inhibitor such as an indolocarbazole and a chemical castration agent is disclosed. A composition containing a tyrosine kinase inhibitor and a chemical castration agent is also disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

**COMBINATION OF TYROSINE KINASE INHIBITOR AND
CHEMICAL CASTRATION TO TREAT PROSTATE CANCER**

Background of the Invention

The invention relates to oncology, endocrinology,
5 andrology, and pharmacology.

Prostate cancer is the most frequently diagnosed
cancer in men and is responsible for approximately 41,000
deaths in the United States annually (Parker, S.L., et
al. (1996) *CA Cancer J. Clin.*, 65:5-27). Early stage,
10 organ-confined, prostate cancer is often managed with
surgery or radiation therapy until the patient dies from
unrelated causes.

Carcinomas such as breast cancer, colon cancer and
adenocarcinoma are characterized by rapid cell division.
15 Consequently, these cancers are amenable to treatment
with chemotherapeutic agents that inhibit rapid cell
division. In contrast, prostate cancer is not
characterized by rapid cell division. Therefore,
conventional chemotherapeutic agents generally display
20 low efficacy against prostatic carcinomas.

Prostatic carcinomas are often sensitive to
hormonal manipulation. Currently approved treatment of
prostrate cancer includes surgical castration, chemical
castration, or a combination of surgical and chemical
25 castration. Removal of the testes, the primary
testosterone producing organ, reduces the levels of
circulating androgens, to less than 5% of normal levels.
This reduction in androgen levels inhibits prostate tumor
growth. Although the anti-tumor effects of surgical
30 castration are direct, the anti-tumor effects can be
temporary. Surgical castration often leads to clonal
selection of androgen-independent prostate tumor cells.

- 2 -

This results in re-growth of the prostate tumor in a form that proliferates without testosterone or DHT stimulation (Isaacs et al. (1981) *Cancer Res.* 41:5070-5075; Crawford et al. (1989) *N. Eng. J. Med.* 321:419-424).

5 Chemical castration (also called medical castration) is often substituted for surgical castration, as an initial treatment. Chemical castration can be achieved by administration of estrogens, e.g., diethylstilbestrol (DES); LHRH analogues, e.g.,
10 leuprolide acetate (LUPRON®) or goserelin acetate (ZOLADEX®); steroidal antiandrogens, e.g., cyproterone acetate (CPA); nonsteroidal antiandrogens, e.g., flutamide, nilutamide, or CASODEX®; or a combination of such agents.

15 Receptor-linked tyrosine kinases are transmembrane proteins that contain an extracellular ligand binding domain, a transmembrane sequence, and a cytoplasmic tyrosine kinase domain. Tyrosine kinases function in cellular signal transduction. Cell proliferation,
20 differentiation, migration, metabolism and programmed death are examples of tyrosine kinase-mediated cellular responses.

 Tyrosine kinases have been implicated in prostate epithelial cell transformation and tumor progression.
25 Implicated tyrosine kinases include Fibroblast Growth Factor (FGF) receptors, Epidermal Growth Factor (EGF) receptors, and Platelet-Derived Growth Factor (PDGF) receptors. Also implicated are Nerve Growth Factor (NGF) receptors, Brain-Derived Neurotrophic Factor (BDNF)
30 receptors, and Neurotrophin-3 (NT-3) receptors, and Neurotrophin-4 (NT-4) receptors.

 U.S. Patent Nos. 5,516,771, 5,654,427 and 5,650,407 discuss indolocarbazole-type tyrosine kinase inhibitors and prostate cancer. U.S. Patent Nos.
35 5,475,110; 5,591,855; and 5,594,009; and WO 96/11933


- 3 -

discuss fused pyrrolocarbazole-type tyrosine kinase inhibitors and prostate cancer.


Summary of the Invention

It has been discovered unexpectedly that tyrosine kinase inhibitors exert their anti-tumor effects against mammalian prostate cancer by a hormone-independent mechanism. It has been further discovered that the combination of tyrosine kinase inhibitor therapy and antihormone therapy can be synergistic.


Based on these discoveries, the invention features a method for treating prostate cancer in a mammal, e.g., a human. The method includes administering a therapeutically effective amount of a tyrosine kinase inhibitor to the mammal, and co-administering a chemical castration agent to the mammal. The tyrosine kinase inhibitor and the chemical castration agent can inhibit prostate tumor progression synergistically. Preferred tyrosine kinase inhibitors include indolocarbazoles. Preferred indolocarbazoles include the following compounds:



Compound II-12;




Compound II-4; and




Compound II-4-LAE.

Compound II-4-LAE is the lysyl- β -alaninate ester of
 Compound II-4, or a pharmacologically acceptable salt of
 the ester, e.g., the dihydrochloride salt. Compound II-
 5 12 is described in U.S. Pat. No. 4,923,986 ("Compound
 20"). Compound II-4 is described in U.S. Pat. No.
 5,461,146. Compound II-4-LAE is described in U.S. Pat.
 No. 5,650,407 (Example 14). The tyrosine kinase
 10 inhibitor also can be be a fused pyrrolocarbazole. The



(Compound II-4); and



(Compound II-4-LAE).

Alternatively, the tyrosine kinase inhibitor in the composition can be a fused pyrrolocarbazole. The composition can be formulated for oral administration or

- 7 -

parenteral administration. The chemical castration agent can be an estrogen, an LHRH analog, or an antiandrogen, or a combination of two or more such compounds. A preferred LHRH analog for inclusion in the composition is leuprolide acetate. A preferred antiandrogen for inclusion in the composition is flutamide. The chemical castration agent included in the composition can be a combination of an LHRH analog and an antiandrogen, for example, leuprolide acetate and flutamide.

As used herein, "chemical castration agent" means a compound that: (1) inhibits the production of serum androgens, (2) blocks binding of serum androgens to androgen receptors, or (3) inhibits the conversion of testosterone to DHT, or a combination of two or more such compounds.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present application, including definitions will control. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference.

Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described below. The materials, methods, and examples are illustrative only and not intended to be limiting. Other features and advantages of the invention will be apparent from the detailed description, and from the claims.

Brief Description of the Drawings

Fig. 1 is a graph of relative tumor volume (fold change) versus time (days) in an in vivo rat prostate tumor model system. Circles, vehicle control; upright

- 8 -

triangles, Compound II-4 monotherapy control; squares, castrate controls; inverted triangles, Compound II-4/castration combination treatment. Compound II-4 dosage was 10 mg/kg, by subcutaneous injection. Compound II-4 administration is indicated by rectangles containing plus signs on the X axis.

Fig. 2 is a graph of relative tumor volume (fold change in Dunning H tumors) versus time (days) in castrated rats. Circles, vehicle control; squares, Compound II-4. Time of Compound II-4 administration is indicated by rectangles on the X axis.

Fig. 3 is a graph of relative tumor volume (fold change) versus time (days) in rats previously treated with Compound II-4. Circles, Compound II-4; squares, Compound II-4/castration treatment. Time of Compound II-4 administration is indicated by rectangles on the X axis.

Fig. 4 is a graph of relative tumor volume (fold change) versus time (days) in an in vivo rat prostate tumor model system. Circles, vehicle control; upright triangles, Compound II-12 monotherapy control; squares, chemically castrated controls receiving leuprolide acetate (LUPRON®); inverted triangles, Compound II-12/leuprolide acetate combination treatment. Compound II-4 dosage was 10 mg/kg BID, per os. Compound II-12 administration is indicated by rectangles on the X axis.

Detailed Description

The co-administration of a tyrosine kinase inhibitor and a chemical castration agent can be by concurrent administration of separate formulations, i.e., a tyrosine kinase formulation and a chemical castration agent formulation. Administration of separate formulations is "concurrent" if the timing of their administration is such that the pharmacological activities of the tyrosine kinase inhibitor and the

- 9 -

chemical castration agent occur simultaneously in the mammal undergoing treatment.

In some embodiments of the invention, co-administration of a tyrosine kinase inhibitor and a chemical castration agent is accomplished by formulating them into a single composition.

Preferably, the dosage of the tyrosine kinase inhibitor is from 1 μ g/kg to 1 g/kg of body weight per day. More preferably, the dosage of the tyrosine kinase inhibitor is from 0.01 mg/kg to 100 mg/kg of body weight per day. The optimal dosage of the tyrosine kinase inhibitor will vary, depending on factors such as type and extent of progression of the prostate cancer, the overall health status of the patient, the potency of the tyrosine kinase inhibitor, and route of administration. Optimization of the tyrosine kinase dosage is within ordinary skill in the art.

Various tyrosine kinase inhibitors suitable for use in this invention are known in the art. Preferably, the tyrosine kinase inhibitor used in this invention is a trk A inhibitor, a trk B inhibitor, or a trk C inhibitor. Suitable indolocarbazole-type tyrosine kinase inhibitors can be obtained using information found in documents such as Dionne et al., U.S. Patent No. 5,516,771, Dionne et al., U.S. Patent No. 5,654,427, Lewis et al., U.S. Patent No. 5,461,146, and Mallamo et al., U.S. Patent No. 5,650,407.

In some embodiments of the invention, Compound II-4-LAE is prepared and administered to a human patient according to the following procedure. Compound II-4-LAE (dihydrochloride) and an osmotically suitable amount of mannitol are dissolved in distilled water, and the pH is adjusted to approximately 3.5. This solution is lyophilized to produce a powder. For storage and convenient use, aliquots of the lyophilized powder containing 27.5 mg of Compound II-4-LAE and 55 mg of

- 10 -

mannitol are prepared. At the time of use, an aliquot of lyophilized powder is redissolved in sterile water for injection, USP, to yield 1.1 ml containing 50 mg/ml mannitol and 25 mg/ml of Compound II-4-LAE

- 5 (dihydrochloride). This reconstituted solution is then diluted with an appropriate volume of 5% Dextrose Injection, USP, for administration of the desired Compound II-4-LAE dose by intravenous infusion over a period of approximately one hour. The dosage of Compound
10 II-4-LAE in this procedure can be conveniently initiated at 1 mg/meter²/day and gradually increased, for example to 64 mg/meter²/day, or 501 mg/meter²/day, as the patient's progress is monitored.

Various chemical castration agents are known.

- 15 Known chemical castration agents useful in this invention are sometimes categorized as follows: estrogens, leuteinizing hormone-releasing hormone (LHRH) agonists, LHRH antagonists, and antiandrogens. Antiandrogens can be further categorized as steroidal or nonsteroidal.

- 20 Estrogens, e.g., diethylstilbestrol (DES), raise sex hormone-binding globulin levels and plasma prolactin levels. This reduces LH secretion and testicular testosterone synthesis through a negative feedback response. Dosage of DES is often from 1 mg/day to 5
25 mg/day. Preferably, higher dosages of DES are avoided because of possible complications relating to cardiovascular risk.

- An LHRH agonist preferred for use in this invention is leuprolide acetate, commercially available
30 as LUPRON® (Takeda Abbott Pharmaceuticals, Inc.). The chemical name of leuprolide acetate is 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate (salt). Leuprolide acetate, an LHRH agonist, is a potent
35 inhibitor of gonadotropin secretion when administered continuously and in therapeutic doses. This effect is

- 11 -

reversible upon discontinuation of leuprolide acetate administration.

Leuprolide acetate, e.g., LUPRON DEPOT®, is believed to act by a negative feedback mechanism. In humans, subcutaneous administration of single daily doses of leuprolide acetate causes an initial increase in serum levels of leuteining hormone (LH). In males, within two to four weeks after initiation of leuprolide acetate administration, serum testosterone falls to castrate levels.

When used in this invention, leuprolide acetate is administered subcutaneously, intramuscularly, or intravenously. Leuprolide acetate can be administered, for example, by subcutaneous injection of 1 mg per day. In some embodiments of the invention, leuprolide acetate is administered in a depot formulation. A depot formulation conveniently provides sustained release of the drug over an extended time period, e.g., 1 to 4 months. An exemplary depot formulation includes a suspension of microspheres containing leuprolide acetate, purified gelatin, DL-lactic and glycolic acids copolymer, and D-mannitol. The microspheres can be suspended in a carrier containing carboxymethylcellulose sodium, D-mannitol, and water. Such a depot formulation is commercially available as LUPRON DEPOT™ (Takeda Abbott Pharmaceuticals) and is suitable for intramuscular injection.

Another LHRH agonist useful in this invention is goserelin acetate, commercially available as ZOLADEX® (Zeneca). The chemical structure of goserelin acetate is pyro-Glu-His-Trp-Ser-Tyr-D-Ser(Bu^t)-Leu-Arg-Pro-Azgly-NH₂ acetate. ZOLADEX® is supplied as a formulation designed for subcutaneous injection with continuous release over a 28-day period.

An example of an LHRH antagonist useful in this invention is ANTIDE® (Ares-Serono), whose chemical name

- 12 -

is D-alaninamide N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N6-(3-pyridinylcarbonyl)-L-lysyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl. Another example of a useful LHRH antagonist is GANIRELIX® (Roche/Akzo Nobel), whose chemical name is N-Ac-D-Nal,D-pCl-Phe,D-Pal,D-hArg(Et)2,hArg(Et)2,D-Ala.

Examples of steroidal antiandrogens are cyproterone acetate (CPA) and megestrol acetate, commercially available as MEGACE® (Bristol-Myers Oncology). Steroidal antiandrogens may block prostatic androgen receptors. They may also inhibit the release of LH. CPA is preferably administered to human patients at dosages of 100 mg/day to 250 mg/day.

Nonsteroidal antiandrogens block androgen receptors. They may also cause an increase in serum LH levels and serum testosterone levels. A preferred nonsteroidal antiandrogen is flutamide (2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl] propanamide), commercially available as EULEXIN® (Schering Corp.). Flutamide exerts its antiandrogenic action by inhibiting androgen uptake, by inhibiting nuclear binding of androgen in target tissues, or both. Flutamide is typically administered orally, e.g., in capsule form. An exemplary flutamide dosage is 250 mg, three times per day, i.e., 750 mg per day.

Another nonsteroidal antiandrogen is nilutamide, whose chemical name is 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-dione. When used in this invention, an exemplary dosage of nilutamide 300 mg daily, followed by a reduced dosage of 150 mg/day.

In some embodiments of the invention, the chemical castration agent is a combination of an LHRH agonist such as leuprolide acetate, and an antiandrogen such as

- 13 -

flutamide or nilutamide. For example, leuprolide acetate can be administered by subcutaneous, intramuscular or intravenous injection, and concurrently the flutamide can be administered orally. The tyrosine kinase inhibitor
5 can be administered separately in a third formulation, or it can be formulated together with the LHRH agonist or the antiandrogen.

Another nonsteroid antiandrogen useful in this invention is CASODEX®. An exemplary dosage of CASODEX®
10 is from 5 mg to 500 mg per day, preferably about 50 mg per day.

An exemplary combined formulation according to this invention includes 1-20 mg of Compound II-12 and 100-1000 mg of flutamide in a capsule for oral
15 administration to a human patient, once, twice, or three times per day. In a preferred embodiment, the formulation includes a vehicle containing polysorbate 80 and polyethylene glycol in a ratio of 1:1 (v/v), to enhance bioavailability of Compound II-12. In some
20 embodiments, this Compound II-12/flutamide oral formulation is supplemented by an intramuscular injection of a leuprolide acetate depot injection, e.g., LUPRON DEPOT®. Another tyrosine kinase such as Compound II-4 or Compound II-4-LAE can be substituted for Compound II-12
25 in this formulation. Other exemplary combined formulations according to this invention include Compound II-12, Compound II-4 or Compound II-4-LAE, and a chemical castration agent, in a single solution suitable for intravenous infusion.

30 Tyrosine kinase inhibitors and chemical castration agents can be formulated, individually or in combination, into pharmaceutical compositions by admixture with pharmaceutically acceptable nontoxic excipients and carriers. Such compositions can be prepared for use in
35 parenteral administration, particularly in the form of liquid solutions or suspensions; for oral administration,

- 14 -

particularly in the form of liquid, tablets or capsules; or intranasally, particularly in the form of powders, nasal drops, or aerosols.

The composition can be administered conveniently
5 in unit dosage form and can be prepared by any of the methods known in the art. Such methods are described, for example, in *Remington's Pharmaceutical Sciences* (Mack Pub. Co., Easton, Pa., 1980).

Liquid dosage forms for oral administration
10 include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compound, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents,
15 solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive,
20 castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents,
25 sweetening, flavoring, and perfuming agents.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the
30 particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are
35 compatible with body tissues.

- 15 -

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, 3) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

- 16 -

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and
5 the like.

The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. In solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose,
10 lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules,
15 tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a
20 delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The invention is further illustrated by the following examples. The examples are provided for illustration purposes only, and they are not to be
25 construed as limiting the scope or content of the invention in any way.

EXAMPLES

Example 1: Compound II-4 Combined with Surgical Castration

30 Data from animal experiments involving tyrosine kinase administration in combination with surgical castration were considered relevant to tyrosine kinase administration in combination with chemical castration.

The Dunning R-3327 H tumor (derived from a
35 spontaneous prostate tumor in an aged Copenhagen rat) was

- 17 -

used in these experiments because of its androgen-sensitivity and its slow growth rate (Isaacs, 1989, Cancer Res. 49:6290-6294). A consideration in the experimental design was that surgical castration of rats
5 harboring Dunning H tumors leads to almost immediate cessation of tumor growth followed by androgen-insensitive tumor regression at about 5-6 weeks post-castration (Isaacs et al. (1981) Cancer Res.41:5070-5075).

10 The Dunning H tumor regression induced by Compound II-4 was not due to an effect on androgen levels, because the experiments were performed in rats implanted with testosterone-releasing silastic capsules. The implanted capsules were designed to maintain circulating
15 testosterone at physiological levels. Serum testosterone levels measured at the end of the experiment confirmed that testosterone was $\geq 1-2$ ng/ml.

The following experiment had three objectives: 1) to determine whether the combination of Compound II-4
20 with surgical castration would provide greater anti-tumor efficacy than Compound II-4 or surgical castration alone;

2) to determine whether Compound II-4 could cause regression of Dunning H tumors that had been selected hormone insensitivity by prior castration of the host
25 animals; and 3) to determine if tumors treated with Compound II-4 for several dosing cycles were still sensitive to surgical castration.

Compound II-4 was synthesized at Cephalon, Inc. and formulated (10 mg/ml) in a vehicle containing 40%
30 polyethylene glycol (PEG 1000, Spectrum, Los Angeles, CA), 10% polyvinylpyrrolidone (C30, ISP Boundbrook, NJ), 2% benzyl alcohol (Spectrum, Los Angeles, CA) in water (48%).

Adult, male, inbred Copenhagen rats (200-240 g)
35 obtained from Harlan Sprague Dawley (Indianapolis, IN)

- 18 -

were maintained three rats/cage and give a commercial diet (Purina Formulab 5001) and water *ad libitum*. Animals were housed under humidity-controlled, temperature-controlled conditions, with a light/dark
5 cycle of 12-hour intervals. Rats were quarantined for one week before experimental manipulation. Rat prostate cancer Dunning R-3327 H tumors were transplanted using trocar pieces. An adult male Copenhagen rat bearing a Dunning H tumor was sacrificed and the tumor was
10 isolated. The tumor was cut, and small pieces were inoculated subcutaneously in adult, male Copenhagen rats.

Experiments were performed under the guidelines of the Johns Hopkins University Animal Care and Use Committee Protocol No. RA91M517 and the Cephalon
15 Institutional Animal Care and Use Committee Protocol No. 03-008.

For surgical castration, rats bearing established Dunning H tumors were anesthetized by intramuscular injection of KETAMINE™ (4.1 mg/100 g body weight) and
20 XYLAZINE™ (0.85 mg/100 g body weight). Each rat was placed on its back. A small incision (0.5-1 cm) was made through the skin at the posterior tip of the scrotum. Another incision was made to break the connective membrane surrounding the testes. The epididymis, testes,
25 vas deferens, the spermatic blood vessels, and the fat were pulled out and severed. Any remaining tissues were pushed back into the sac, and the incision was closed with autoclips. The autoclips were removed 5-7 days following surgery.

30 Thirty six Dunning H tumor-bearing rats (0.9-18 cm³ in size) were divided into four groups of nine animals each. Group 1 served as a vehicle control. Group 2 was castrated on Day 1. Group 3 received injections of Compound II-4 (10 mg/kg, sc) as described below. Group 4
35 was castrated on Day 1 and given injections of Compound II-4 as described below. Groups 1 and 3 were implanted

subcutaneously (in the flank) with a 2 cm long sealed silastic tube filled with testosterone on Day 1. A silastic implant of this size was suitable to maintain serum testosterone in the physiological range of 1-3 ng/ml chronically for a duration of six months. Compound II-4 was administered sub-cutaneously (10 mg/kg/day) to Groups 3 and 4 on a periodic, 5-day dosing cycle with approximately 10 days between cycles. The drug was administered on Days 1-5, 14-18, 29-33 and 42-46. The drug vehicle was administered to Groups 1 and 2 on the same schedule as the Compound II-4-treated groups.

Eight rats from Group 2 were divided into two groups of four rats each on Day 60. One group was treated with Compound II-4, 10 mg/kg, (subcutaneous) for 5 days, followed by drug withdrawal for 9 days, followed by a second five-day dosing regime at 10 mg/kg/day (subcutaneous). The second group received vehicle on the same dosing schedule.

Seven rats derived from Group 3 of the preceding experiment were divided into two groups on Day 60. One group (N=3) of rats was castrated. Both groups were treated with Compound II-4, 10 mg/kg (subcutaneous) for 5 days, followed by drug withdrawal for 9 days, followed by a second five-day dosing regime as before.

Tumors were measured on anesthetized animals (isofluorane vapor for approximately 1-2 minutes) at indicated intervals using a vernier caliper. Tumor volume was calculated using the formula: $V(\text{cm}^3) = .5236 \times \text{length}(\text{cm}) \times \text{width}(\text{cm}) \times [(\text{length}(\text{cm}) + \text{width}(\text{cm}))/2]$.

The Dunnett's test, Mann-Whitney Rank Sum Test, Paired t Test, or Signed Rank Test of significance was applied for statistical analysis using the SigmaStat program.

The growth of Dunning H tumors in intact, vehicle-treated rats was linear, and an approximately 3.5-fold increase in tumor volume over 60 days was observed (Fig.

- 20 -

1). Surgical castration caused a rapid regression of tumors, i.e., 25% by Day 5. Tumor re-growth in castrated rats was observed by Day 12, and complete recovery of the regressed tumor volume was achieved by Day 38.

5 Compound II-4 alone (10 mg/kg, sc; 4 independent cycles of Compound II-4 treatment: 5 days of drug treatment followed by drug withdrawal for approximately 10 days) caused complete tumor growth inhibition or induced tumor regression. The average tumor volume in
10 drug-treated animals was significantly smaller ($p < 0.01$) than in vehicle treated control animals after each cycle of Compound II-4 administration (days 5, 19, 34 and 47; data not shown). In addition, each cycle of Compound II-4 administration caused regression relative to tumor
15 volume at the start of each dosing cycle (data not shown).

 The combination of Compound II-4 with surgical castration caused complete inhibition of tumor growth or induced tumor regression (Fig. 1). Overall, the
20 combination of Compound II-4 administration and surgical castration was significantly more effective than surgical castration alone. *In vivo* tumor re-growth was observed after Compound II-4 withdrawal in both castrated and non-castrated animals. However, re-growth was minimal in
25 castrated animals ($p < 0.01$, Fig. 1).

 These results demonstrated that Compound II-4 can be used in combination with surgical castration to maximize degree and/or duration of regression of tumors in an accepted *in vivo* model of prostate cancer.

30 Further experiments were conducted to determine whether Compound II-4 treatment causes regression of tumors selected to be hormone insensitive via prior androgen ablation. Eight rats from the castrated group of the preceding experiment (no prior treatment with
35 Compound II-4) were divided into two groups of four rats each on Day 60. One group was treated with Compound II-

- 21 -

4, 10 mg/kg, sc for 5 days followed by drug withdrawal for 9 days followed by a second five-day dosing regime at 10 mg/kg/day, sc. The second group received vehicle on the same dosing schedule.

5 Treatment with Compound II-4 caused a significant regression of androgen-insensitive Dunning H tumors grown in castrated rats by Day 3 ($p < 0.05$; Fig. 2). Maximal regression was observed by Day 6 ($p < 0.05$). Drug withdrawal allowed the tumors to re-grow. However, the
10 tumor volume in Compound II-4 treated rats was significantly less ($p < 0.05$) than vehicle treated animals even 10 days after the end of first Compound II-4 cycle. Dunning H tumors selected to be hormone insensitive via prior androgen ablation were still sensitive to the anti-
15 tumor action of Compound II-4.

Experiments were also conducted to determine whether prior Compound II-4 treatment of rats bearing Dunning H tumors could cause selection of tumors insensitive to subsequent androgen ablation via surgical
20 castration. Seven rats from Compound II-4 treated group of the preceding experiment were divided into two groups on Day 60. One group ($N=3$) was castrated as described above. Both groups were treated with Compound II-4, 10 mg/kg, sc for 5 days followed by drug withdrawal for 9
25 days followed by a second five day dosing regime as before. Surgical castration caused a non-statistically-significant regression of tumors that had undergone four prior cycles, and two concurrent cycles, of Compound II-4 treatment (Fig. 3). Overall, the data indicated that
30 repeated exposure to Compound II-4 did not select an androgen-insensitive population of Dunning H tumors.

Castration, Compound II-4 treatment, and the combination of Compound II-4 with surgical castration was well tolerated. Limited mortality was observed in
35 control and castrated groups of animals treated with vehicle or Compound II-4. In each case, mortality

- 22 -

occurred at the time of tumor measurement, presumably due to anesthesia overdose.

EXAMPLE 2:

Combination of Compound II-12

5 and Chemical Castration

Compound II-12 was synthesized at Cephalon, Inc. Compound II-12 dihydrochloride was formulated (10 mg/ml) in a vehicle containing 3:2 (v/v) Gelucire (Gattefosse, Saint-Priest, France) in propylene glycol (Spectrum, 10 Gardena, CA).

Adult, male, inbred, Copenhagen rats (200-240 g) obtained from Harlan Sprague Dawley (Indianapolis, IN) were used in this experiment. Maintenance and manipulation of the rats, and transplantation of Dunning 15 R-3327 H tumors, was as described in Example 1 (above).

Forty six rats (weight: 380 ± 8 g) harboring Dunning H tumors ($1/6-33.2$ cm³ in size) were divided into four groups. Group 1 (N=12) served as vehicle control (1 ml/kg, po BID, Days 0-20 and 31-45). Group 2 (N=10) was 20 treated with leuprolide acetate (LUPRON DEPOT®) (5.2 mg/kg, sc on Days 0 and 21. Group 3 (N=12) received Compound II-12 (10 mg/kg, po BID on Days 0-20 and 31-45). Group 4 (N=12) received a combination of leuprolide acetate (5.2 mg/kg, sc on Days 0 and 21) and Compound II- 25 12 (10 mg/kg, po BID on Days 0-20 and 31-45). Animals of groups 1 and 3 were implanted sc with a 2 cm long silastic capsule filled with testosterone.

Tumor measurements and statistical analyses were performed as described in Example 1 (above).

30 In vivo growth of the Dunning H tumors was consistent in vehicle-treated animals. An approximately 2.5-fold increase in tumor volume was observed by Day 53. Initiation of each Compound II-12 treatment cycle (10 mg/kg BID, po for 21 days with an interim drug free 35 period of ten days) inhibited Dunning H tumor growth and caused marked tumor regression. Inhibition of tumor

- 23 -

growth observed in the Compound II-12 treatment group was statistically significant, as compared with the vehicle control group. This difference was observed from the earliest tumor measurement, i.e., Day 4, until
5 termination of the experiment). Leuprolide acetate treatment alone also resulted in tumor regression. Slow tumor re-growth was observed approximately 32 days after initiation of leuprolide treatments (Fig. 4).

As compared to leuprolide alone, or Compound II-12
10 alone, the Compound II-12/leuprolide combination was significantly more effective ($p < 0.05$) in maintaining a reduced rate of tumor growth than either treatment alone (Fig. 4). Tumor regrowth was observed in the
15 Compound II-12 treatment group and the leuprolide treatment group, approximately thirty days after initiation of treatments. In contrast, the combination treatment group exhibited a longer duration of reduced tumor growth and was statistically different from the
20 Compound II-12 group and the leuprolide group from days 35 and 39 respectively, until termination of the experiment on Day 54 ($p < 0.05$; Fig. 4).

These experimental results demonstrated that the combination Compound II-12 with chemical castration was synergistic in anti-tumor efficacy (Figs. 1 and 4).

25 Other embodiments are within the following claims.


- 24 -

Claims

We claim:


1. A method for inhibiting prostate tumor progression in a mammal, comprising administering a
5 therapeutically effective amount of a tyrosine kinase inhibitor to the mammal, and co-administering a therapeutically effective amount of a chemical castration agent to the mammal, thereby inhibiting prostate tumor progression.
- 10 2. The method of claim 1, wherein the mammal is a human.
3. The method of claim 1 wherein the therapeutically effective amount of a tyrosine kinase inhibitor and the therapeutically effective amount of the
15 chemical castration agent inhibit tumor progression synergistically.
4. The method of claim 1, wherein the tyrosine kinase inhibitor is a *trkA* inhibitor, a *trkB* inhibitor, or a *trkC* inhibitor.
- 20 5. The method of claim 1, wherein the tyrosine kinase inhibitor is an indolocarbazole.

6. The method of claim 5, wherein the indolocarbazole has the following structure:




(Compound II-12).

7. The method of claim 5, wherein the indolocarbazole has the following structure:



(Compound II-4).

8. The method of claim 5, wherein the indolocarbazole has the following structure:



(Compound II-4-LAE).

9. The method of claim 1, wherein the tyrosine
5 kinase inhibitor is a fused pyrrolocarbazole.

10. The method of claim 1, wherein the tyrosine
kinase inhibitor is administered orally.

11. The method of claim 1, wherein the tyrosine
kinase inhibitor is administered parenterally.

10 12. The method of claim 1, wherein the chemical
castration agent is selected from the group consisting of
an estrogen, an LHRH agonist, an LHRH antagonist, and an
antiandrogen.

- 27 -

13. The method of claim 12, wherein the LHRH agonist is leuprolide acetate.

14. The method of claim 12, wherein the antiandrogen is flutamide.

5 15. The method of claim 1, wherein the chemical castration agent is a combination of an LHRH agonist and an antiandrogen.

16. The method of claim 15, wherein the LHRH agonist is leuprolide acetate, and the antiandrogen is
10 flutamide.

17. The method of claim 1, wherein the tyrosine kinase inhibitor and the chemical castration agent are administered in separate formulations.


18. The method of claim 1, wherein the tyrosine
15 kinase inhibitor and the chemical castration agent are formulated together in a single composition.

19. A composition comprising a tyrosine kinase inhibitor and a chemical castration agent.

20. The composition of claim 19, wherein the
20 tyrosine kinase inhibitor is a *trkA* inhibitor, a *trkB* inhibitor, or a *trkC* inhibitor.


21. The composition of claim 19, wherein the tyrosine kinase inhibitor is an indolocarbazole.

22. The composition of claim 21, wherein the
25 indolocarbazole is selected from the group consisting of: an indolocarbazole whose structure is:



(Compound II-12);


an indolocarbazole whose structure is:



(Compound II-4); and

an indolocarbazole whose structure is:

- 29 -



(Compound II-4-LAE).

23. The composition of claim 19, wherein the tyrosine kinase inhibitor is a fused pyrrolocarbazole.

24. The composition of claim 19, wherein the
5 composition is formulated for oral administration.

25. The composition of claim 19, wherein the composition is formulated for parenteral administration.

26. The composition of claim 19, wherein the chemical castration agent is selected from the group
10 consisting of an estrogen, an LHRH agonist, an LHRH antagonist, and an antiandrogen.

27. The composition of claim 26, wherein the LHRH agonist is leuprolide acetate.

- 30 -

28. The composition of claim 26, wherein the antiandrogen is flutamide.

29. The composition of claim 19, wherein the chemical castration agent is a combination of an LHRH
5 agonist and an antiandrogen.

30. The composition of claim 29, wherein the LHRH agonist is leuprolide acetate, and the antiandrogen is flutamide.

1/4




FIG. 1

2/4






FIG. 2

3/4

**FIG. 3**

4/4



SUBSTITUTE SHEET (RULE 26)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 45/06, 31/55	A3	(11) International Publication Number: WO 99/08668 (43) International Publication Date: 25 February 1999 (25.02.99)
(21) International Application Number: PCT/US98/16849 (22) International Filing Date: 13 August 1998 (13.08.98) (30) Priority Data: 60/055,891 15 August 1997 (15.08.97) US (71) Applicant (for all designated States except US): CEPHALON, INC. [US/US]; 145 Brandywine Parkway, West Chester, PA 19380 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DIONNE, Craig, A. [US/US]; 106 Victoris Court, Downingtown, PA 19335 (US). ISAACS, John [US/US]; 13638 Poplar Hill Road, Phoenix, MD 21131 (US). VAUGHT, Jeffry, L. [US/US]; 206 Kathleen Way, Glenmoore, PA 19343 (US). (74) Agent: CREASON, Gary, L.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 15 April 1999 (15.04.99)
(54) Title: COMBINATION OF TYROSINE KINASE INHIBITOR AND CHEMICAL CASTRATION TO TREAT PROSTATE CANCER (57) Abstract A method of treating prostate cancer by coadministering a tyrosine kinase inhibitor such as an indolocarbazole and a chemical castration agent is disclosed. A composition containing a tyrosine kinase inhibitor and a chemical castration agent is also disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/16849

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K45/06 A61K31/55

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 654 427 A (MURAKATA CHIKARA ET AL) 5 August 1997 cited in the application see abstract ---	1-30
A	US 5 516 771 A (MURAKATA CHIKARA ET AL) 14 May 1996 cited in the application see abstract ---	1-30
X,P	GEORGE DANIEL J_(A): "Combined effects of the Trk tyrosine kinase inhibitor, CEP-751 (KT-6587), and castration on the growth of Dunning H rat prostate cancers in vivo." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, 1998, vol. 39, 1998, page 664 XP002092523 see the whole document --- -/--	1-30

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

8 February 1999

Date of mailing of the international search report

18/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Leherte, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/16849

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DIONNE C A_(A) S: "Inhibition of prostate tumor growth by the trk-selective tyrosine kinase inhibitor, CEP-751 (KT-6587)." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, 1997, vol. 38, no. 0, 1997, page 634 XP002092524 see abstract	1-30
A	----- LAVELLE FRANCOIS: "Tyrosine protein kinase inhibitors in oncology: The end of the beginning? (Annual Congress of the American Association of Cancer Research San Diego, California, USA, April 12-16, 1997)." BULLETIN DU CANCER (PARIS), 1997, vol. 84, no. 7, July 1997, pages 769-770, XP002092525 -----	1-30

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/16849

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-18
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/16849

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5654427 A	05-08-1997	US 5516771 A	14-05-1996
		AT 165097 T	15-05-1998
		AU 679752 B	10-07-1997
		AU 6960794 A	20-12-1994
		CA 2163904 A	08-12-1994
		DE 69409641 D	20-05-1998
		DE 69409641 T	26-11-1998
		EP 0699204 A	06-03-1996
		EP 0839814 A	06-05-1998
		ES 2118414 T	16-09-1998
		FI 955709 A	03-01-1996
		NO 954816 A	26-01-1996
		WO 9427982 A	08-12-1996
US 5516771 A	14-05-1996	US 5654427 A	05-08-1997
		AT 165097 T	15-05-1998
		AU 679752 B	10-07-1997
		AU 6960794 A	20-12-1994
		CA 2163904 A	08-12-1994
		DE 69409641 D	20-05-1998
		DE 69409641 T	26-11-1998
		EP 0699204 A	06-03-1996
		EP 0839814 A	06-05-1998
		ES 2118414 T	16-09-1998
		FI 955709 A	03-01-1996
		NO 954816 A	26-01-1996
		WO 9427982 A	08-12-1994